{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T04:23:15Z","timestamp":1784953395334,"version":"3.55.0"},"reference-count":12,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["CFTY720DUS37T"],"award-info":[{"award-number":["CFTY720DUS37T"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01 NS 49577-6"],"award-info":[{"award-number":["R01 NS 49577-6"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Tumor necrosis factor alpha (TNF-alpha) inhibitors, such as infliximab, are commonly used to treat rheumatoid arthritis (RA) and other immune-mediated disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To determine whether infliximab-associated central nervous system (CNS) demyelination can be differentiated from multiple sclerosis (MS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We present a case of pathologically proven CNS demyelination in a patient treated with infliximab and describe clinical\u2013radiographic\u2013neuropathological findings. Putative mechanisms of TNF-alpha inhibitor-associated CNS demyelination are described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and conclusion:<\/jats:title>\n                    <jats:p>Infliximab treatment is associated with CNS inflammatory demyelinating activity, which is histopathologically indistinguishable from MS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1352458519894710","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T06:58:35Z","timestamp":1576565915000},"page":"1124-1129","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["Pathological findings in central nervous system demyelination associated with infliximab"],"prefix":"10.1177","volume":"26","author":[{"given":"Alicja","family":"Kalinowska-Lyszczarz","sequence":"first","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA\/Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahboobeh","family":"Fereidan-Esfahani","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia F","family":"Lucchinetti","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8141-2394","authenticated-orcid":false,"given":"W Oliver","family":"Tobin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"key":"bibr1-1352458519894710","unstructured":"Highlights of Prescribing Information: Remicade (infliximab), https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/103772s5374lbl.pdf (1998, accessed 1 July 2019)."},{"key":"bibr2-1352458519894710","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410300510"},{"key":"bibr3-1352458519894710","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.3.457"},{"key":"bibr4-1352458519894710","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"bibr5-1352458519894710","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q"},{"key":"bibr6-1352458519894710","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W"},{"key":"bibr7-1352458519894710","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-017-0785-3"},{"key":"bibr8-1352458519894710","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519828601"},{"key":"bibr9-1352458519894710","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.08.029"},{"key":"bibr10-1352458519894710","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000205"},{"key":"bibr11-1352458519894710","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-2494(97)87239-2"},{"key":"bibr12-1352458519894710","doi-asserted-by":"publisher","DOI":"10.1177\/135245859600100619"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458519894710","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1352458519894710","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458519894710","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:01:26Z","timestamp":1777694486000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1352458519894710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,17]]},"references-count":12,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1177\/1352458519894710"],"URL":"https:\/\/doi.org\/10.1177\/1352458519894710","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,17]]}}}